摘要
目的探讨法舒地尔对早期糖尿病肾病患者血清转化生长因子-β1和单核细胞趋化因子1水平的影响。方法将早期2型糖尿病肾病患者100例随机分为A组(对照组,50例)和B组(50例)。两组均给予常规治疗,B组在常规药物治疗同时给予法舒地尔注射液30mg+生理盐水50m L,2次/d,静脉泵入,连用2周。用ELISA法检测两组患者治疗前后血清转化生长因子-β1和单核细胞趋化因子1水平的变化。结果 A组治疗前后血清转化生长因子-β1和单核细胞趋化因子1水平比较,差异无统计学意义(P>0.05),B组治疗后血清转化生长因子-β1和单核细胞趋化因子1水平较治疗前下降(P<0.05),A组与B组治疗后比较,两项指标的差异均有统计学意义(P<0.05)。结论在常规治疗的基础上加用法舒地尔注射液,可降低转化生长因子-β1和单核细胞趋化因子1水平,对早期糖尿病肾病具有良好的治疗效果。
Objective To explore the changes of serum TGF-β1 and MCP-1 in diabetic nephrosis patients after treated with Fasudil injection. Methods 100 early diabetic nephrosis patients were randomly divided into the group A（ control group ,50 cases）and group B （50 cases）. All patients received routine therapy, while patients in group B were additionally given fasudil injection for 2 weeks. The level of serum TGF-β1 and MCP-1 were measured by the ELISA before and after the treatment. Results After the treatment, the levels of TGF-β1 and MCP-1 in group A had not significant changes（P 〉0.05）,While the levels of TGF-β1 and MCP-1 in group B after treatment were much lower than that of before treatment（P 〈 0.05 ）. The decrease of TGF-β1 and MCP-1 were more significant in group B than that of in group A after treatment （P 〈 0.05 ）. Conclusion On the basis of routine therapy,Fasudil injection could inhibit the expression of TGF-β1 and MCP-1, which has good curative effect on early diabetic nephrosis.
出处
《标记免疫分析与临床》
CAS
2015年第6期525-527,共3页
Labeled Immunoassays and Clinical Medicine
